The availability of the conjugated vaccines and the results of CAPITA studies have had a fundamental influence on the USA and EU recommendations for pneumococcal vaccination. [5, 6] In the US, these recommendations, issued by the Advisory Committee on Immunization Practices, are consistent for the whole country. This is not the case in Europe, where each country has modifications according to age or risk factors and budget. In this issue of Annals of Thoracic Medicine, a group of Saudi experts provides recommendations for pneumococcal vaccination. The most important aspect of these guidelines is the recommendation of universal vaccination of all adults over 50 years of age.
This recommendation is based on the following arguments:
(1) High prevalence of sickle-cell disease, which is a disease with a high risk for S. pneumoniae infection; (2) high prevalence of chronic diseases in younger age groups; (3) prescription of over-the-counter antibiotics in private pharmacies, which increases the risk of S. pneumoniae resistant to antibiotics. In addition, very importantly, Saudi Arabia has to face a unique every year situation because of the Hajj and Umrah season, in which there is an increased risk of respiratory tract infections, including S. pneumonia. [7] The panel of experts from the Saudi Thoracic Society believes that these arguments justify the recommendation for the universal pneumococcal vaccine in patients over 50 years of age. [8] 
